SNDX Q3 2017 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$305,000+0.0% YoY

Gross Profit

$305,000100.0% margin

Operating Income

-$15M-5064.3% margin

Net Income

-$15M-4946.9% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$124M

Total Liabilities

$28M

Stockholders' Equity

$97M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$305,000	$305,000	+0.0%
Gross Profit	$305,000	$305,000	+0.0%
Operating Income	-$15M	-$15M	-1.4%
Net Income	-$15M	-$15M	-0.8%